IRLAB Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-110.01	-83.13	-177.84	-113.41	51.78
Depreciation & Amortization	4.32	4.58	4.32	3.72	3.22
Other Amortization	-	-	-	0.26	0.26
Asset Writedown & Restructuring Costs	-	-	-	0.8	-
Other Operating Activities	8.73	3.96	-	-	39.09
Change in Accounts Receivable	5.68	2.79	3.63	3.63	-12.81
Change in Other Net Operating Assets	36.06	6.21	5.04	-37.62	47.11
Operating Cash Flow	-55.22	-65.59	-164.85	-142.61	128.64
Capital Expenditures	-	-0.2	-0.29	-2.88	-0.71
Sale (Purchase) of Intangibles	-	-	-	-0.5	-
Investing Cash Flow	-	-0.2	-0.29	-3.38	-0.71
Long-Term Debt Issued	18.8	25	27.28	-	-
Long-Term Debt Repaid	-19.95	-3.6	-3.61	-3.13	-2.87
Net Debt Issued (Repaid)	-1.15	21.4	23.68	-3.13	-2.87
Issuance of Common Stock	74.56	-	-	-	-
Other Financing Activities	-0	-	-	-	-0.18
Financing Cash Flow	73.41	21.4	23.68	-3.13	-3.05
Miscellaneous Cash Flow Adjustments	-	0	-	0	-
Net Cash Flow	18.19	-44.39	-141.47	-149.12	124.89
Free Cash Flow	-55.22	-65.79	-165.14	-145.49	127.93
Free Cash Flow Margin	-96.10%	-69.52%	-2908.47%	-237.97%	61.57%
Free Cash Flow Per Share	-0.82	-1.27	-3.18	-2.81	2.47
Cash Interest Paid	12.5	6.52	0.2	0.3	0.8
Levered Free Cash Flow	-22.29	-38.77	-99.98	-103.57	69.69
Unlevered Free Cash Flow	-11.04	-32.22	-99.86	-103.38	69.92
Change in Working Capital	41.74	9	8.67	-33.99	34.3

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.